On the other hand, neoadjuvant therapy has gained an expanding role in the management of breast cancer, not only in the locally advanced setting but also in patients with early breast cancer with pathological types that are expected to achieve a complete response, namely Human Epidermal growth factor receptor (Her)2-enriched and triple-negative subtypes [19]. This evidence concerns the gene ERBB2 and breast cancer.